Department of Medicine Archive — Page 62 of 121
-
May 27, 2021
Arroyo awarded Harold Amos Medical Faculty Development grant from Robert Wood Johnson Foundation
Juan Pablo Arroyo, MD, PhD, has been awarded the Harold Amos Medical Faculty Development Grant from the Robert Wood Johnson Foundation, the nation’s largest philanthropy dedicated solely to health. -
May 26, 2021
Vanderbilt researchers present new data on clinical trials at ASCO 2021
Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year. -
May 26, 2021
VUMC researchers receive grant from the National Heart, Lung, and Blood Institute to develop biomarkers to improve the diagnosis of acute heart failure
Researchers at Vanderbilt University Medical Center (VUMC) have received a four-year, $6.2-million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop a novel panel of biomarkers to improve the diagnosis of acute heart failure (AHF). -
May 25, 2021
Heat for hypertension in autonomic failure
Heat therapy could offer a novel nonpharmacologic approach for treating the overnight hypertension that affects patients with autonomic failure. -
May 20, 2021
Beta cell regeneration
Vanderbilt researchers dissected the complex microenvironment of the pancreatic islet to discover the signals that drive beta cell regeneration — as a possible treatment for diabetes. -
May 20, 2021
Type 2 diabetes medication shown to benefit asthma patients
Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation. -
May 20, 2021
VUMC is pacesetter for national aspirin study
According to an innovative large-scale clinical trial reported last week in the New England Journal of Medicine, a single daily baby aspirin (81 mg) or a single daily adult aspirin (325 mg) are equally safe and effective for prevention of adverse cardiovascular events for patients with established atherosclerotic cardiovascular disease.